[1]Drazic A，Myklebust LM，Ree R，et al.The world of protein acetylation［J］.Biochim Biophys Acta，2016，1864(10)：1372-1401.
[2]Ler SY，Leung CH，Khin LW，et al.HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population［J］.Oncol Rep，2015，34(5)：2238-2250.
[3]Wurmbach E，Chen YB，Khitrov G，et al.Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma［J］.Hepatology，2007，45(4)：938-947.
[4]Bruix J，Boix L，Sala M，et al.Focus on hepatocellular carcinoma［J］.Cancer Cell，2004，(3)：215-219.
[5]Chen WQ，Zheng RS，Baade PD，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66(2)：115-132.
[6]Lv GS，Chen L，Wang HY.Research progress and prospect of liver cancer in China［J］.Chinese Bulletin of Life Sciences，2015，27(3)：237-248.［吕桂帅，陈磊，王红阳.我国肝癌研究的现状与前景［J］.生命科学，2015，27(3)：237-248.］
[7]Van Dyke.Lysine deacetylase（KDAC) regulatory pathways：An alternative approach to selective modulation［J］.Chem Med Chem，2014，9(3)：511-522.
[8]Mutze K，Langer R，Becker K，et al.Histone deacetylase（HDAC) 1 and 2 expression and chemotherapy in gastric cancer［J］.Ann Surg Oncol，2010，17(12)：3336-3343.
[9]Weichert W，Roske A，Gekeler V，et al.Histone deacetylases 1，2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy［J］.Br J Cancer，2008，98(3)：604-610.
[10]Hulsurkar M，Li Z，Zhang Y，et al.Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1［J］.Oncogene，2017，36(11)：1525-1536.
[11]Zhao H，Yu Z，Zhao L，et al.HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy［J］.Jpn J Clin Oncol，2016，46(10)：893-902.
[12]Kramer OH.HDAC2：A critical factor in health and disease［J］.Trends Pharmacol Sci，2009，30(12)：647-655.
[13]Muller BM，Jana L，Kasajima A，et al.Differential expression of histone deacetylases HDAC1，2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression［J］.BMC Cancer，2013，13：215.
[14]Buurman R，Gurlevik E，Schaffer V，et al.Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells［J］.Gastroenterology，2012，143(3)：811-820.
[15]Noh JH，Jung KH，Kim JK，et al.Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins［J］.PLoS One，2011，6(11)：e28103.
[16]Lee YH，Seo D，Choi KJ，et al.Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2［J］.Cancer Res，2014，74(17)：4752-4761.
[17]Wang F，Qi Y，Li X，et al.HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9［J］.Clin Invest Med，2013，36(2)：E87-E94.
[18]Song C，Zhu S，Wu C，et al.Histone deacetylase（HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase（MMP) 2 and 9 expression［J］.J Biol Chem，2013，288(39)：28021-28033.